| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.18 | 0.003 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.089 | 0.005 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |